Alternative Titleホルモン感受性前立腺癌における、ホルモン治療開始3か月後のPSA値は全生存期間の予測マーカーである
Note (General)Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.<br/>Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of≥8 (p=0.004), an extent of disease value (EOD) of≥2 (p=0.004), and a 3-month PSA level>1% of the pretreatment level (p=0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level>1% of the pretreatment level was an independent predictor of OS (p=0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level>1% of the pretreatment level correlated with a poor prognosis.
Collection (particular)国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
Date Accepted (W3CDTF)2022-08-08T06:02:54+09:00
Data Provider (Database)国立国会図書館 : 国立国会図書館デジタルコレクション